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Spinal Osteoporosis
Charles H. Chesnut III, MD*

O

steoporosis remains the most common of the metabolic
bone diseases. Nevertheless, it is only in the past two decades that the academic community, the practicing physician,
the patient, and the media have recognized the morbidity and
economic health care costs of this disease, particularly to the
aging population. An example of the evolution of osteoporosis'
recognition in the academic sphere is the relative time and space
allotment for previous Henry Ford Hospital Intemational Symposia. In the first (1972) International Symposium, "Clinical
Aspects of Metabolic Bone Disease," a three-hour afternoon
session with eight presented papers was devoted to osteoporosis;
the subsequent publications occupied 62 pages of the 694-page
volume of the Proceedings. At the second (1983) Intemational
Symposium, "Clinical Disorders of Bone and Mineral Metabolism," osteoporosis occupied four hours of the program, with 11
presented papers encompassing 59 pages of the 552-page Proceedings. For the current 1988 Intemational Symposium, an entire day was directed toward information on osteoporosis, with a
morning session devoted to spinal osteoporosis, and an afternoon session to metabolic bone disease of the hip. A total of 17
presented papers comprised the osteoporosis presentations; undoubtedly a major portion of the Proceedings will be devoted to
this disease. In 1988, it would appear that appropriate recognition of osteoporosis and its complications has occurred.

Osteoporosis: 1988 and Beyond
Peck (1) provided a timely introduction to the session on
spinal osteoporosis, timely in that this session corresponded to
the beginnings of National Osteoporosis Week. He gave an
informative overview of progress in the field during the 1980s,
noting particular advances in understanding the regulation of
bone remodeling, in developing techniques for quantitating
bone mass (particularly the new x-ray based procedures), and in
devising preventive therapeutic programs. He noted that prevention is currentiy the most important therapeutic strategy in osteoporosis; estrogen therapy remains the major prophylactic
modality but cannot and should not be utilized by all women.
Altemative antiresorptive strategies are available, such as calcitonin and possibly the diphosphonates; in addition, on the
horizon are numerous other antiresorptive and even bone-restorative approaches. The 1980s have been a most productive
time for osteoporosis research, but obviously much remains to
be accomplished.

teoporosis syndromes: type I , and type II. They noted the similarity of the type II osteoporosis to a Gompertzian disease
model; ie, a degenerative disease with an exponentially increasing incidence rate with aging, an early-onset and insidious progression and later symptomatic threshold, a multifactorial
etiology, a common occurrence in the population at large, and a
lack of response to treatment. Type I osteoporosis, on the other
hand, resembles a non-Gompertzian disease model: a lack of an
exponential increase with age, an acute onset after the menopause, a less common occurrence in the population at large, a
specific pathophysiology or pathogenesis—estrogen deficiency,
and a greater potential response to treatment. While currently
available data do not definitively prove the heterogeneity of osteoporosis and the presence of type I and type 11 osteoporosis
syndromes, such an obviously thoughtful and intellectually
challenging approach to the epidemiological pathogenesis
of osteoporosis was stimulating and led to an invigorating
discussion.

Appropriate Use of Bone Densitometry
Genant et al (3) reviewed the current status of bone densitometry, noting the technical capabilities of the three
noninvasive techniques for quantitating bone mass: single and
dual photon absorptiometry, computed tomography, and the
new x-ray dual energy technique. They discussed the controversy regarding bone mass quantity as a primary determinant of
fracturerisk,noting that while the areas of controversy are under
clinical and epidemiological investigation, critical management
decisions must be made for the current female population at risk
for, or already affected with, osteoporosis. In this regard, the
authors noted, as Wasnich et al have indicated, that bone mass is
a continuous variable with fracture the primary outcome. Individuals with low bone density may not have yet had a fracture,
but this does not mean that they are free of osteoporosis; the
probability of fracture is increased, and fractures display a probabilistic nature. Genant et al noted that most investigators accept
usage of bone mass quantitation to detect low bone mass (and
presumably an increased risk for fracture) in individuals with
secondary osteoporosis (athletic amenorrhea, chronic steroid
therapy, etc), but that there is no consensus regarding their use in
assessing the need for estrogen therapy and in assessing the
presence and severity of osteoporosis generally. In terms of
screening for osteopenia (either "mass screening" or "selective
screening"), a definitive recommendation could not be made;

Rirtlier Characterization of tiie Heterogeneity of
tlie Osteoporotic Syndromes
Melton and Riggs (2) offered an innovative epidemiological
approach in support of their hypothesis of two heterogeneous os-
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this remains an area of considerable medical, political, and financial controversy. Even "selective screening" of individuals
with a suggestive history of osteopenia and the presence of multiple risk factors is not universally accepted as a reasonable
clinical tool, due to some evidence suggesting that historically
based risk factors, alone or in combination, have limited predictive value for fracture risk in the individual patient. Genant et al
noted appropriately that the progress in improving precision
with rectilinear single photon absorptiometry scanning, x-ray
based dual photon absorptiometry, and automatic image analysis quantitative computed tomography have enabled the clinician to monitor efficacy of treatment intervention with a higher
degree of certainty than was possible in the past.

Developing Strong Bones: The Teenage Female
The presentations and discussions then shifted to a consideration of female populations not usually thought of in the context
of osteoporosis (ie, the teenager, the young adult, and the premenopausal and perimenopausal female) and the determinants
of bone mass within these premenopausal populations.
Matkovic and Dekanic (4) reiterated the hypothesis that peak
bone mass at skeleton maturity (age 10 to 20) is a major determinant of postmenopausal bone mass; a low bone mass at skeleton maturity presumably contributes to low postmenopausal
bone mass and presumably increases the risk for subsequent
fracture. In addition, data were presented from multiple sources
noting that the demands for skeletal calcium are highest during
the adolescent growth spurt (the time of peak bone mass attainment), that calcium deficiency at this time can decrease the degree of positive calcium balance and presumably the amount of
bone mass, and that calcium intake is deficient (below the RDA)
in many American adolescent females. While such observations
are validated by current data, it was noted in subsequent discussion that no definitive data currently exist demonstrating that increasing and/or repleting calcium intake in adolescent females
increases bone mass over control groups. Nevertheless, the concept of developing maximal peak bone mass in adolescence to
protect against further osteoporosis appears most reasonable.

Preserving Strong Bones:
The Young Adult Female
From a consideration of factors contributing to the development of adequate bone mass, the session then tumed to factors
for preserving peak bone mass. Drinkwater (5) agreed that
failure to achieve one's maximal potential bone mass during the
young adult years is a risk factor for subsequent osteoporotic
fracture, but she also noted that a genetic component to maximal
attainable bone mass precludes all women being equally successful in reaching bone mass levels presumed to be protective.
She did, however, point out that all women can make changes in
their life-styles to maximize their potential bone mass gain and
minimize their bone mass loss. Alcohol, caffeine, and tobacco
are three possible negative risk factors for preserving bone mass
in the premenopausal years. More importantly, three variables
known to have a positive effect on premenopausal bone mass in-
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clude the maintenance of a normal menstrual cycle, adequate
calcium intake, and adequate physical activity. In terms of the
menstrual cycle, normal levels of estrogen (as determined by
normal menstrual cycles) are necessary for maintenance of bone
mass during a woman's young adult years. The role of calcium
in preserving bone mass remains controversial, as do the overall
effects of increasing physical activity, although current data
support physical activity increases to be effective in increasing
bone mass in women across a wide range of ages. However,
Drinkwater's studies in amenorrheic athletes raise questions
about the abilities of exercise to preserve bone if estrogen levels
are inadequate. Obviously, normal menses, adequate calcium
intake, and adequate exercise are important in preserving bone
mass; it also appears that the lack of any single factor cannot be
completely compensated for by increasing the other two factors.
Preserving bone mass prior to the menopause is an area that will
receive much attention in the future.

Optimizing Bone Mass in the
Perimenopause: Calcium
The session then considered perimenopausal and immediate
postmenopausal bone loss. Heaney (6) noted four components
of perimenopausal bone loss, including age-related bone loss,
bone loss associated with estrogen deficiency, bone loss associated with calcium deficiency, and bone loss associated with
other factors, such as alcoholism, etc. A hypothetical model incorporating thefirstthree of these factors was presented. Heaney
concluded from the model that while estrogen deficiency is a
major contributor to bone loss immediately after the menopause
(in the "young elderly"), it is a less prominent contributor later
on (10 to 20 years postmenopausal, the "old elderly"). In the
later years, calcium intake may be a more important contributor
to bone loss than estrogen deficiency. Indeed, when evaluated in
the Heaney model (assuming a 20 mg/day calcium loss), calcium deficiency accounts for 50% more bone loss than does estrogen deficiency 20 to 30 years after the menopause.
Heaney also reiterated current concems regarding the absorbability of calcium from various calcium sources, noting that
most food sources have readily absorbable calcium, but that a
number of calcium supplements and pills may have difficulties
with dissolution and resultant absorbability.
Heaney pointed out that despite the current controversies regarding the importance of calcium in the prevention of immediately postmenopausal bone loss, an intake of 1,000 mg/day of
calcium for estrogen-replete perimenopausal women and 1,500
mg/day for estrogen-deprived postmenopausal women is "safe
and prudent." He also reiterated the fundamentally sound observation that while not all postmenopausal bone loss is due to calcium deficiency, such a deficiency does contribute to some bone
loss. Since there is no way to distinguish individuals whose bone
loss is due to calcium deficiency from those whose loss is due to
other contributing factors, it is reasonable to ensure a calcium
intake at the NIH recommendations noted above. Calcium deficiency, then, does appear to be a significant contributor to bone
loss, with, however, its greatest effects later in the postmenopausal period.
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Optimizing Bone Mass in the
Perimenopause: Estrogen
Undoubtedly, estrogen deficiency is the main contributor to
significant bone loss immediately (one to ten years) after the
menopause, and this was again reinforced by Christiansen and
Riis (7), who in reviewing laboratory data designated estrogen
deficiency as the most important variable in immediately
postmenopausal bone loss. They reinforced the now well-documented conclusions that estrogen and/or progesterone replacement therapy can prevent the progression of bone mass loss after
the menopause, at all skeletal sites studied to date. However, defining the woman's individual risk for subsequent bone loss, as
well as her need for estrogen replacement therapy, remains difficult; definitive identification of at-risk women by various blood
and urine parameters and bone mass quantitating techniques has
not yet been possible. Nevertheless, current data certainly support estrogen replacement therapy as the primary therapeutic
modality for the prophylaxis of osteoporosis.

Optimizing Bone Mass in the Perimenopause:
Calcitonin and Diphosphonates
Alternatives to calcium and estrogen for optimizing bone
mass in the perimenopausal woman were then discussed (8).
Calcitonin and the diphosphonates (biphosphonates) are additional therapeutic agents for preventing bone loss, primarily by
inhibition of bone resorption. Synthetic salmon calcitonin is
safe and has proven efficacy in osteoporotic individuals; in addition, one study by Stevenson et al has shown it to be equivalent
to estrogen in prevention of bone loss in immediately postmenopausal women without osteoporosis. However, the drug is
currentiy available in most countries only as an injectable agent,
which is unsuitable for prophylactic use; a nasal spray is available, and results of some, but not all, preliminary studies with
this preparation appear promising. Expense of the calcitonin
preparations currently available remains a problem. The biphosphonates (such as etidronate) are reasonable candidates for
prophylactic usage in that they are relatively safe when given intermittentiy, are relatively inexpensive, and are orally administered; their therapeutic efficacy, however, remains unproved.
Studies in osteoporotic females are inconclusive with these
agents, and there are no studies currentiy available in the immediately postmenopausal women in whom the biphosphonates are
utilized for prophylaxis. Nevertheless, these two potential prophylactic therapies, biphosphonates and calcitonin, have the attribute of safety; such safety is a significant asset when compared to estrogen. Estrogens can prevent bone loss over an
extended period of time but occasionally at a high cost in terms
of side effects.

Use of Vitamin D Metabolites in Osteoporosis
Presentations on the treatment of the osteoporotic woman
were confined to a discussion of vitamin D therapy. Gallagher
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(9) noted a therapeutic rationale for the vitamin D congeners: a
correction ofthe calcium malabsorption present in many osteoporotic patients, subsequent improvement of calcium balance, and, possibly, in high dosage, stimulation of bone formation. He reviewed the currently somewhat disparate data
regarding usage of l,a(OH)D3 and l,25(OH)2D in the osteoporotic individual, concluding that the vitamin D metabolites
may have a beneficial effect on bone mass, but unfortunately at
dosage levels frequently associated with significant renal toxicity. The role of the D metabolites in the therapy of osteoporosis
remains undefined.

Steroids and Osteoporosis:
An Unsolvable Problem?
The session concluded with consideration of a somewhat different topic; corticosteroid-induced osteopenia. Raisz (10) confronted this difficult problem, noting that this clinical entity is
not "an unsolvable problem" as was intimated in his titie, but,
on the other hand, was currently unsolved at present. He reviewed the current understandings regarding the mechanism of
corticosteroid action on bone and considered the therapeutic dilemma confronting the clinician in treating steroid-induced osteopenia, including the major problem of reversing the inhibitory effects of glucocorticoids on bone formation. The dilemma
is compounded by the inability to predict accurately which
steroid-treated patients will develop osteoporosis and fractures.
As Raisz noted, however, progress is being made in the laboratory in leaming more about the pathogenesis of corticosteroidinduced osteopenia, including regulation of bone cells, and
about new classes of factors stimulating bone growth. Nevertheless, at the present time, it is unfortunately necessary to
consider altematives to corticosteroids when possible or to utilize the lowest possible dosage of cortisone both to treat the underiying problem and to spare the skeleton.

Final Note
The session closed with a final discussion of the topics considered; the new and innovative data presented, particularly by
Melton and Riggs (2), Drinkwater (5), and Heaney (6), received
much attention. Again, the obvious increased interest developing in osteoporosis over the past two decades was much in evidence throughout the session.
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